News >

Experts Highlight Benefits and Challenges With Biosimilars in Breast Cancer

Ellie Leick
Published: Tuesday, Jan 21, 2020

Ruth O'Regan, MD, a professor of medicine, Hematology/Oncology Division, at University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center

Ruth O'Regan, MD

FDA-approved trastuzumab (Herceptin) biosimilars are expected to decrease the financial toxicity of breast cancer treatment, according to shared perspectives by Ruth O'Regan, MD, and Adam M. Brufsky, MD, PhD, FACP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication